Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2015 Mar 19;4(3):e001897.
doi: 10.1161/JAHA.115.001897.

Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications

Joakim Alfredsson  1 , Matthew T Roe  1
Affiliations
Editorial

Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications

Joakim Alfredsson et al. J Am Heart Assoc. .
No abstract available

Keywords: Editorials; arteriosclerosis; platelets; prevention; thrombin.

PubMed Disclaimer

Comment on

References

    1. Leger AJ, Covic L, Kuliopulos A. Protease‐activated receptors in cardiovascular diseases. Circulation. 2006; 114:1070-1077. - PubMed
    1. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KWInvestigators T. Thrombin‐receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012; 366:20-33. - PubMed
    1. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SACommittee TPTS, Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012; 366:1404-1413. - PubMed
    1. Magnani G, Bonaca MP, Braunwald E, Dalby AJ, Fox KAA, Murphy SA, Nicolau JC, Ophuis TO, Scirica BM, Spinar J, Theroux P, Morrow DA. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015; 4:e00150510.1161/JAHA.114.001505 - PMC - PubMed
    1. Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DAInvestigators TRAP‐TSC. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 P‐TIMI 50 trial. Lancet. 2012; 380:1317-1324. - PubMed